Lejeune Underground
heart and soul of our Camp Lejeune and Jacksonville community
Login - Create Account - Help
Clean out your garage on Lejeune bookoo! Or find local garage sales on Yard Sale Search.com
PCSing? Win the lottery? Explore Camp Lejeune Housing courtesy of Military Real Estate!

Finally heard from St. Jude...

who's talking here?

Q♠ 1
IMSleepngbty 1
supercalifragilistic 1
Cancer Sucks!!! 2
CupCake 1
Monkey Manners 1
*Yayamalden** 1

     » send to friend     » save in my favorites     » flag dangerous topic flag as a dangerous topic

Cancer Sucks!!! --- 17 years ago -

Not what we wanted to hear. The doctor said after looking over Connor's medical records it sounds like he starting to become toxic from the chemo and here pretty soon we will probably have to make the decision to do radiation. He said whole brain radiation and spine are his best hope but it does come with MAJOR side effects such as mental retardation and paralysis just to name a few. The other option he gave us besides a ersection of the tumor is a Phase II clinical trial of Avastin/CPT11. It has had good results in high grade gliomas (Connor's is considered low grade with high grade features) but the risk is bleeding around the tumor. So no matter what option we choose it is not a good thing. His oncologist at UNC said there are 2 more options that have not been tested in PMAs but may have a good possibility. So now we are looking at high dose Tamoxifen (yep the breast cancer treatment) or a study that comes out this summer of Valproic Acid and some other drug. So right now we are really confused on what to do since if he has a resection he may not be able to have to avastin & cpt11 due to the bleeding. Who knows. I figured I'd update since some of you knew we were contacting St. Jude. 

IMSleepngbty --- 17 years ago -

I wasn't sure if you had head of this trial or not. You may want to contact them to see if there is a trial for Connor. I don't know. I'm just throwing in my 2 cents. Glioma Drug Targeted At Brain Tumors Shows Promise In Phase 1 Trial 07 Nov 2007 A drug developed and tested at UAB (University of Alabama at Birmingham) targeted at malignant brain tumors known as glioma has shown promising results in a Phase 1 trial, according to results presented at the American Society for Therapeutic Radiology and Oncology annual meeting. The findings indicate that an intravenous formulation of TM-601 can cross the blood brain-barrier and bind to tumor tissue in the brain. TM-601 is a synthetic version of chlorotoxin, a naturally occurring peptide derived from scorpion venom. It was developed by scientists at UAB and TransMolecular, Inc., a biotechnology company which funded the current study. "This Phase 1 study provides important data demonstrating that TM-601 can cross the blood-brain barrier, which is an obstacle in the development of drugs for brain cancer," said John Fiveash, M.D., associate professor of radiation oncology at UAB and primary investigator of the trial. "TM-601 may emerge as a promising new therapeutic drug for glioma patients, a community with significant unmet needs due to the current lack of drug treatments." TM-601 binds with certain receptors on malignant tumor cells in the brain, without affecting nearby healthy cells. As it binds with tumor cells, it can deliver a targeted dose of radiation that kills the tumor cell. Previous studies have involved introducing the drug directly to tumor cells through the skull. Fiveash says the current study was intended to determine if the drug could be delivered intravenously. "We intravenously administered TM-601 to five patients with recurrent gliomas," Fiveash said. "All five demonstrated specific uptake of the drug, indicating that it had successfully crossed the blood-brain barrier." "Additionally, one patient showed a reduction in the volume of enhancement of the tumor on a MRI scan, suggesting possible tumor response to treatment," he said. "Since the drug was safe at the tested dose, we anticipate a larger dose may be able to be given without a high risk of toxicity." Glioma is a particularly invasive form of brain cancer that does not respond well to current surgical or medical treatment options. There are 36,000 primary brain tumors reported each year, and nearly half are high-grade gliomas. Half of those with high-grade glioma die within the first year. The discovery that scorpion-based chlorotoxin bound with certain malignant cells in brain tumors was first reported in 1996 by a UAB team led by Harald Sontheimer, Ph.D., professor of neurobiology and director of the UAB Civitan Research Center. TransMolecular, Inc. is a privately held, venture capital backed biotechnology company committed to discovering, developing and commercializing novel and proprietary products to diagnose and treat cancers that have inadequate treatment alternatives. NOTE: The University of Alabama at Birmingham is a separate, independent institution from the University of Alabama, which is located in Tuscaloosa. Please use University of Alabama at Birmingham on first reference and UAB on second reference. University of Alabama at Birmingham 701 20th St. S., AB 1320 Birmingham, AL 35294-0113 United States http://main.uab.edu 

*Yayamalden** --- 17 years ago -

I am so sorry. I hope everything works out with the treatments. 

Cancer Sucks!!! --- 17 years ago -

Thanks! 

CupCake --- 17 years ago -

I hope for stregnth, health and clarity for you and your family! 

Q♠ --- 17 years ago -

I'll be thinking about Connor. What ever you choose to do, I hope it's a success. 

supercalifragilistic --- 17 years ago -

Prayers for you and your family, CS. Wisdom to pick between a rock and a hard place, and lots of strength for all of you. 

Monkey Manners --- 17 years ago -

Prayers for you and your family, CS. Wisdom to pick between a rock and a hard place, and lots of strength for all of you. What she said!!!! Man, some of us don't even know how blessed we are. I can't imagine what you are going through. :( 

page 1
Login to add your comments!

see more discussions about...

Terms of Service - Privacy Policy - Ice Box

Lejeune Underground